Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
4SC AG
4SC, Institute of Molecular Virology sign pact to develop influenza therapies
May 8th, 2006
4SC AG (VSC), a German drug discovery and development company based in Martinsried, and the Institute of Molecular Virology of the University of Munster, Germany, jointly announced that they will cooperate in the development of an active agent suitable for the treatment of influenza virus infections. There is a significant need for medical treatment of infections caused by influenza viruses. The occurrence of highly pathogenic virus strains in Asia and in Turkey, the so-called H5N1 avian influenza (bird flu) viruses, and the associated risk of a possible pandemic in humans emphasizes the current need for antiviral drugs. The research group at the...
Source: Biotech Week (2006-05-08)
|
